77,895 Shares in Aurinia Pharmaceuticals Inc $AUPH Bought by Wakefield Asset Management LLLP

Posted by Stanley Muller on May 16th, 2026

Wakefield Asset Management LLLP purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 77,895 shares of the biotechnology company’s stock, valued at approximately $1,242,000. Wakefield Asset Management LLLP owned 0.06% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of AUPH. Northwestern Mutual Wealth Management Co. acquired a new stake in Aurinia Pharmaceuticals in the third quarter valued at $48,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Aurinia Pharmaceuticals by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 1,318 shares during the period. State of Alaska Department of Revenue acquired a new stake in Aurinia Pharmaceuticals in the third quarter valued at $91,000. Cornerstone Investment Partners LLC acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at $178,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in Aurinia Pharmaceuticals in the third quarter valued at $137,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, May 1st. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.25.

View Our Latest Research Report on Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock opened at $15.28 on Friday. Aurinia Pharmaceuticals Inc has a one year low of $7.28 and a one year high of $16.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.01 and a current ratio of 5.55. The business has a fifty day moving average of $15.28 and a two-hundred day moving average of $15.10. The company has a market cap of $1.97 billion, a P/E ratio of 7.04 and a beta of 1.44.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. The company had revenue of $77.71 million during the quarter, compared to the consensus estimate of $76.98 million. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%. As a group, analysts predict that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Kevin Tang purchased 516,439 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was acquired at an average price of $13.99 per share, with a total value of $7,224,981.61. Following the purchase, the director directly owned 11,845,939 shares of the company’s stock, valued at $165,724,686.61. This represents a 4.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.20% of the stock is owned by company insiders.

About Aurinia Pharmaceuticals

(Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.